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Background: Quadriplegia is a severe, catastrophic injury that predominantly affects people early in life, resulting in
lifelong physical disability. Obstructive sleep apnoea is a direct consequence of quadriplegia and is associated with
neurocognitive deficits, sleepiness and reduced quality of life. The usual treatment for sleep apnoea is nasal
continuous positive airway pressure (CPAP); however, this is poorly tolerated in quadriplegia. To encourage patients
to use this therapy, we have to demonstrate that the benefits outweigh the inconvenience. We therefore propose a
prospective, multinational randomized controlled trial of three months of CPAP for obstructive sleep apnoea after
acute quadriplegia.
Methods/design: Specialist spinal cord injury centres across Australia, New Zealand, the UK and Canada will recruit
medically stable individuals who have sustained a (new) traumatic quadriplegia (complete or incomplete second
cervical to first thoracic level lesions). Participants will be screened for obstructive sleep apnoea using full, portable
sleep studies. Those with an apnoea hypopnoea index greater than 10 per hour will proceed to an initial three-
night trial of CPAP. Those who can tolerate CPAP for at least 4 hours on at least one night of the initial trial will be
randomized to either usual care or a 3-month period of auto-titrating CPAP. The primary hypothesis is that
nocturnal CPAP will improve neuropsychological functioning more than usual care alone. The secondary hypothesis
is that the magnitude of improvement of neuropsychological function will be predicted by the severity of baseline
sleepiness measures, sleep fragmentation and sleep apnoea. Neuropsychological tests and full polysomnography
will be performed at baseline and 3 months with interim measures of sleepiness and symptoms of autonomic
dysfunction measured weekly. Spirometry will be performed monthly. Neuropsychological tests will be
administered by blinded assessors. Recruitment commenced in July 2009.
Discussion: The results of this trial will demonstrate the effect of nocturnal CPAP treatment of obstructive sleep
apnoea in acute quadriplegia. If CPAP can improve neurocognitive function after injury, it is likely that rehabilitation
and subsequent community participation will be substantially improved for this group of predominantly young and
severely physically disabled people.
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Spinal cord injury (SCI) is one of the most severe disabil-
ities a person may sustain. The resultant loss of physical in-
dependence can lead to a significant requirement for
assistance with personal care and activities of daily living,
with consequent loss of privacy and compromised auton-
omy. The cost to the individual in terms of vocational op-
portunities and achievements can be extremely high. The
cost to the community, in terms of lost work capacity, re-
duced ability to utilize prior education and training and the
financial costs of disability pensions, carers’ pensions, at-
tendant care, respite care, equipment and environmental
adaptations, is associated with burden and reduced quality
of life. In Australia, the annual incidence of SCI is approxi-
mately 15 per million [1,2]. Therefore, each year in
Australia 260 people sustain a SCI and of these 57% will
lose full function in their arms and legs (quadriplegia).
Quadriplegia affects 130 to 150 people per year in
Australia [3]. The lifetime costs of the injury are sub-
stantial, even though the numbers affected are relatively
small. In 2009, Access Economics estimated the lifetime
healthcare cost of each incident case of quadriplegia in
Australia to be $9.5million, with the total cost of SCI es-
timated at $2.0 billion [3]. The majority of SCI patients
sustain their injuries in their second or third decade of
life. If those who do not survive the first year following
injury are excluded from analysis, then life expectancy
approaches that of the general population [2]. Thus, if
any secondary disease or impairment were a direct con-
sequence of the SCI, it would have a significant effect
for many years. Obstructive sleep apnoea (OSA) is such
a condition.
The prevalence of sleep-disordered breathing, predom-
inantly OSA, in quadriplegia is two to five times higher
[4-11] than in the general population [12]; however, the
reasons for this increased prevalence remain unclear. A
prospective longitudinal examination of the sleep and
breathing of all new patients with acute quadriplegia
who attended a specialist spinal unit over an 18 month
period found a prevalence of OSA of up to 83% in the
first year after injury [13]. Sleep and respiratory studies
were performed immediately after acute quadriplegia in
30 subjects (25 men) and at 2 weeks and 1, 3, 6 and 12
months post injury. Three subjects (10%) had probable
OSA before their injury. However, 60% had OSA by 2
weeks after injury, 83% at 3 months and 62% at 1 year.
These findings have been confirmed in another centre
[14]. It is thus apparent that that the prevalence of OSA
was extremely high in the first year after injury and that
OSA is a direct consequence of acute quadriplegia.
Untreated OSA is a significant issue for those with
quadriplegia. Previous authors have demonstrated that
OSA in quadriplegia results in significant neurocognitive
deficits [15]. Sajkov et al. demonstrated that hypoxiaduring sleep in subjects with quadriplegia and untreated
OSA was associated with deficits in attention, concentra-
tion, memory and learning. Further, the neurocognitive
impairments were both statistically and clinically signifi-
cant in people with both quadriplegia and OSA, when
compared with normal population values. These deficits
are likely to prolong rehabilitation substantially, reducing
future independence and limiting vocational outcomes
following injury.
The usual treatment for OSA is continuous positive air-
way pressure (CPAP), which corrects sleep hypoxia and
improves neurocognitive performance [16] and nocturnal
blood pressure control [17] in the able-bodied with OSA.
Reports of CPAP treatment in quadriplegia in uncontrolled
studies are disappointing, with low levels of compliance
with therapy reported. Stockhammer et al. [10] found 31
cases of sleep-disordered breathing after screening 50 sub-
jects with quadriplegia. Only 16 of the 31 had previously
used CPAP, with 11 (35%) continuing to use the device for
at least a few weeks. Burns et al. undertook a cross-
sectional postal survey of patients of a US Veterans Affairs
Spinal Cord Service whose record indicated diagnosis or
treatment for OSA [18]. Of those identified, only 39% were
using CPAP at the time, while an additional 27% had used
CPAP but had discontinued therapy owing to intolerance.
In our previously described cohort study [13], five of the
subjects were suspected clinically of having OSA and treat-
ment with CPAP was offered. Only one of the subjects
continued with CPAP for more than a few days, and that
subject only did so after a period of respiratory failure. The
reasons for this poor adherence are multifactorial, but the
most commonly reported complaints are nasal congestion,
an inability to fall asleep with the mask on and a lack of
perceived benefit or noticeable change in symptoms.
In summary, it is known that OSA is a direct conse-
quence of acute quadriplegia and that it is associated with
cognitive deficits likely to impair rehabilitation after injury.
Moreover, although CPAP is the usual treatment for OSA,
it is poorly tolerated in quadriplegia. If the detection, treat-
ment and adherence to CPAP therapy are to be improved
in these patients, further research is vital. We propose to
perform a prospective multicentre randomized controlled
trial of CPAP for OSA after acute quadriplegia.
In preparation for this trial, the Melbourne research
team completed a one-year feasibility study of this project
[19]. The primary aim of the feasibility study was to deter-
mine the feasibility of CPAP treatment for OSA following
acute quadriplegia. All patients (n = 44) with new quadri-
plegia who presented to the Austin Hospital during the
nine months of study recruitment were eligible for study
inclusion. Participants were tested for OSA with the Somté
PSG (Compumedics, Abbotsford, Australia) and those with
OSA were offered treatment with an auto-titrating CPAP
device for three months. Rates of patient accrual,
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ately reflected initial estimates. The feasibility study find-
ings suggested that this current trial would confirm that
OSA is associated with significant sub-acute morbidity and
that CPAP treatment will be associated with an improve-
ment in clinical outcomes.
The specific aim of the COSAQ study is to determine
the effect of nocturnal auto-titrating CPAP treatment on
neuropsychological function, quality of life, autonomic
dysfunction and breathing in people with acute quadriple-
gia and OSA. To address this aim, one primary and two
secondary hypotheses were developed and will be tested.
The primary hypothesis is that usual care and nocturnal
CPAP treatment will improve neuropsychological func-
tioning more than will usual care alone; specifically, work-
ing memory as tested on the Paced Auditory Serial
Addition Test (PASAT). The first secondary hypothesis is
that the magnitude of improvement in neuropsychological
function will be predicted by the severity of baseline
sleepiness (Karolinska Sleepiness Scale (KSS)), sleep frag-
mentation (Sleep Efficiency, Arousal Index) and sleep ap-
noea (apnoea hypopnoea index (AHI), percentage total
sleep time with SpO2 < 90%). The second secondary
hypothesis is that usual care and nocturnal CPAP will im-
prove the following parameters more than usual
care alone:
1. Sleepiness and symptoms: Karolinska Sleepiness
Scale (KSS) and the Basic Nordic Sleep
Questionnaire (BNSQ).
2. Lung Function: spirometry.
3. Quality of life: Assessment of Quality of Life
(AQoL).
4. Autonomic dysfunction: event diary and heart rate
variability.
5. Health utility: AQoL-derived change in utility and
associated quality-adjusted life years (QALY).
6. Depression and anxiety: Hospital Anxiety and




The trial is funded by the Transport Accident Commission
of Victoria. The COSAQ study is an element of the ‘Sleep
Health in Quadriplegia’ five-year programme grant.
Design
A prospective multicentre randomized controlled trial
will be undertaken. The control group will receive usual
care and the experimental group will receive 3 months
of nocturnal CPAP using an auto-titrating CPAP device.
The trial is being conducted in 10 specialist SCI units in
Australia, New Zealand, the UK and Canada. Ethicalapproval has been obtained from the Human Research
Ethics Committee at each site and at the Austin Hospital
(EC00204). Informed consent will be provided prior to
recruitment and participation. Subject recruitment com-
menced at Austin Health in July 2009 and subsequently
at the other sites, as they became ready. Recruitment is
scheduled to finish mid-2015.
Participants
Participants will be recruited from consecutive admis-
sions at the trial sites.
Inclusion criteria
 Acute, traumatic quadriplegia (T1 or higher lesion,
complete or incomplete).
 Older than 18.
Exclusion criteria
 Successful CPAP therapy for OSA prior to injury.
 Significant head injury (Glasgow Coma Score < 8 at
first assessment).
 Ongoing hypercapnic ventilatory failure (PaCO2 >
45 mmHg at time of consent).
 Probable inability to be followed up until three
months.
 Condition likely to significantly limit CPAP use (for
example, major psychoses, facial or base of skull
fractures).
General testing procedures
All testing will be performed at the participants’ bed-
sides. The respiratory function, questionnaires and other
subjective data are collected at the same time in the
mid-afternoon for each subject, to control for possible
circadian influences. Sleep studies will commence at the
subject’s usual bedtime. Figure 1 illustrates the study re-
cruitment and data collection flowchart.
Post-enrolment data collection
The listed information is collected at baseline following
witnessed, informed consent. Human ethics approval has
been provided for witnessed oral consent to be obtained
where impaired upper limb function limits the ability of
potential participants to provide written consent.
1. Demographic information (age at injury, sex, date
of injury).
2. Time and date of assessment.
3. Current lesion level and completeness (Abbreviated
Injury Scale score).
4. Medical history.




























































































Figure 1 Flowchart of COSAQ study participant flow.
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7. Whether the subject has any intercurrent illness.
8. Likelihood of undiagnosed, pre-existing OSA
(Multivariate Apnoea Prediction Index [20].
9. Abdominal girth at end-expiration and neck
circumference.
10.Sleep studies.
The presence of OSA will be assessed using a portable
sleep monitoring device, which comprehensively mea-
sures respiratory and sleep variables. (Compumedics™
Somté PSG, Abbottsford, Australia). All studies will be
sleep-staged and respiration-scored by an independent
trained sleep scientist. Sleep will be staged in 30-second
epochs, arousals marked and respiratory events scored
according to international standard criteria [21]. Sum-
mary indices and statistics will be calculated. Heart rate
variability will be calculated from the ECG trace taken
during quiet resting (prior to sleep onset).
All participants with an apnoea hypopnoea index
(AHI) ≥ 10 will be considered as positive OSA cases and
will proceed to have baseline measures (below) taken.
Baseline measures
A number of tests are made prior to the trial of CPAP
and randomization.
Cognitive test battery
 Rey Auditory Verbal Learning Test.
 Digit Span sub-test of the Wechsler Adult
Intelligence Scale Revised.
 Paced Auditory Serial Addition Test (PASAT).
 Symbol Digit Modalities Test.
 National Adult Reading Test.
All these tests have been previously employed to show
neurocognitive limitation in those with quadriplegia and
OSA [15]. They are all administered orally, so that written
replies or motor responses are not required. This battery of
tests takes approximately 40 minutes to complete and
measures function in the following areas: short-term mem-
ory, attention and concentration, immediate memory span,
cognitive flexibility, internal scanning, working memory,
visual perception, visual attention and concentration. Pre-
vious authors have found that patients with quadriplegia
and OSA had deficits in attention, concentration, memory
and learning skills [15]. The significance of poor function
in these areas is greater in the quadriplegic population,
owing to their limited physical functioning. As a result,
cognition becomes even more important for optimal par-
ticipation in rehabilitation and society. Moreover, it is to be
expected that performance on these tests will be improved
by CPAP treatment.Sleep symptoms and functional consequences of sleepiness
The Basic Nordic Sleep Questionnaire (BNSQ) [22] has
been validated in a spinal cord injured population and
will provide additional information about sleep quality.
Quality of life and health utility values
The Assessment of Quality of Life (AQoL) [23] is a gen-
eric quality of life instrument and has been found to be as
good as or better than instruments commonly used in
measuring outcomes in stroke, co-ordinated care, influ-
enza, cochlear implants, population monitoring and eld-
erly groups. The AQoL provides both health-related
quality of life information in the domains of ‘illness’, ‘inde-
pendent living’, ‘social relationships’, physical senses’, ‘psy-
chological wellbeing’ and a total AQoL value. In addition
to these outcomes, the AQoL may be summarized to gen-
erate utility values, thereby enabling the generation of
quality-adjusted life years (QALY) and facilitating eco-
nomic analyses.
Other tests
In addition, the Hospital Anxiety and Depression Scale
(HADS) and the Profile of Mood States (POMS) tests
will be used.
Pre-randomization procedure
All subjects who fulfil the inclusion criteria, are not ex-
cluded by the exclusion criteria, consent to participate
and are classified with positive OSA will be trialled on
auto-titrating CPAP (Resmed AutoSet, San Diego, USA)
for up to three nights.
Subjects who are able to use the CPAP for at least four
hours on any night will then be randomized as soon as
they have succeeded in doing so, into either the treat-
ment or usual care group. If four hours’ use are tolerated
on the first night, subjects will be randomized at this
time. Those who do not use the CPAP for four hours on
any of the three nights will cease participation in the
trial. The four-hour cut off was derived from the feasibil-
ity trial, where those who were unable to achieve this
time were not likely to be compliant over the length of
the trial.
The decision to randomize only those who are likely to
be adherent with CPAP was the most significant study
design modification to arise from the feasibility study. A
rate of nonadherence of 50%, as was observed in the feasi-
bility study, would render this study unfeasible. Pre-
randomization selection potentially limits the study
generalizability to those who are tolerant of CPAP, al-
though it accurately reflects clinical practice (you would
never ‘force’ patients to use a therapy they did not accept),
was strongly supported by the Australasian Sleep Trials
Network, is a similar protocol to that employed in the
multinational Sleep Apnoea Cardiovascular Endpoints
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by reducing the numbers of subjects, the timeframe and
the associated staff cost.
Randomization
Randomization will be performed centrally using the re-
search study database [25]. A blocked, randomization se-
quence was generated [26] and loaded into the online
database by an independent member of the research unit
prior to trial commencement. Allocation concealment is
assured through the site design, which requires subject
enrolment be completed before randomization can be-
come possible. Additionally, the randomized group is
only revealed after a commitment to randomization is
both made and confirmed.
Weekly measures
The following measures will be made at baseline and
then weekly upon review:
1. Time and date of assessment.
2. Current medications.
3. Any intercurrent illness.
4. Sleepiness, using the Karolinska Sleepiness Scale
(KSS) [27], a ten-item scale, which describes current
sleepiness (state).
5. Machine usage data in the CPAP treatment group
will be downloaded weekly, and those subjects in the
CPAP treatment group will be reviewed with respect
to any machine usage or masking issues.
6. Clinical review, autonomic dysfunction assessment
and troubleshooting.
All participants will be provided with an autonomic
dysfunction symptom diary (Table 1). The diary will rec-
ord the number, nature and treatment of symptoms typ-
ically related to autonomic dysreflexia.
Monthly measures
Respiratory function will be measured at baseline and then





Pounding headache, which gets worse
Flushing and blotching of the skin above
the level of the spinal cord injury
Profuse sweating
Chills without fever
Hypertension (high blood pressure)
In the last week, have you experienced any of the following symptoms, and if
so, were they treated?supine position. Simple spirometry will be used to obtain
vital capacity and forced expiratory volume in 1 second.
All tests of respiratory function will be performed without
an abdominal binder and in accordance with the perform-
ance limitations imposed by quadriplegia [28].End study (three months or hospital discharge) data
collection
The baseline testing battery will be repeated in the same
manner with the exception of the Multivariate Apnoea
Prediction Index. Following the completion of all testing
procedures, a semistructured subject interview will be held
with a subset of the trial participants to examine their ex-
perience of the trial and to explore themes related to ad-
herence. The sleep study will be repeated, with the subjects
using their CPAP (or not) as randomized. At this time, par-
ticipants will be provided with full details of their physio-
logical tests and referred for ongoing clinical management
of any OSA if they wish.
An adverse event audit will be performed at the conclu-
sion of the study. This process will be overseen by an inde-
pendent outcomes committee comprising two sleep or
spinal specialist clinicians. The patient medical record will
be audited for all adverse events defined by the outcomes
committee. The blinded assessor at each site will perform
the audit. The outcomes committee will review the stan-
dardized audit report and will classify any defined event by
severity and whether it was or was not likely to have been
associated with study treatment or assessment procedures.
These classified event reports will be passed to the inde-
pendent data monitoring and review committee for review.Treatment device
Participants in the treatment group will be fitted with a
nasal or face mask and head gear. The choice of patient
interface will be made locally by the treating teams. The
CPAP will be delivered by an auto-titrating device
(Resmed AutoSet, San Diego USA). These devices auto-
matically set the level of delivered pressure to ensure
upper airway patency, thereby eliminating the need for a
pressure titration sleep study to be performed in the
sleep laboratory. In addition, if, as was observed in the
pilot study, effective CPAP alters over the trial period
[19], the device will alter the delivered pressure accord-
ingly to maintain airway patency.
The AutoSet devices record the number and type of
respiratory events detected, the pressure delivered in re-
sponse to these events and the amount of time that the
machine was on and delivering pressure to a patient. If
the machine is running, but the mask has been removed
from the face, this time does not contribute to the meas-
ure of CPAP compliance.
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The research team have completed a one-year study
examining the feasibility and safety of the planned proto-
col. No major adverse events were observed; in particular,
no episodes of excess uncontrolled flow, such that exhal-
ation was impeded by the auto-titrating CPAP were ob-
served [19]. One device was found to be faulty and
exchanged. This fault did not affect any participant. All
minor adverse events (mask irritation, nasal stuffiness) re-
lated to acclimatization to CPAP and are common to all
new CPAP users.Implementation
A member of the research team will instruct the pa-
tients, their families and the ward staff in the use of the
CPAP. The ward staff will introduce, apply and adjust
the mask for comfort, until the participants are satisfied.
The research staff will also review the subjects each
morning to identify any barriers to use and address any
difficulties. The feasibility study suggested that CPAP ad-
herence could be maximized through early and careful
attention to any difficulties.
Treatment duration
In the able-bodied with OSA, a minimum of 6 weeks of
treatment is required to establish CPAP adherence and to
observe changes in neuropsychological functioning out-
comes. Three months of therapy has been demonstrated as
sufficient to improve neurocognitive functioning, specific-
ally improved memory, in the able-bodied with OSA [29].
Other cardiovascular changes occur more slowly; however,
improvements would be evident after three months of
therapy. We propose to treat people for three months or
until hospital discharge.
Data analysis
All analyses will be performed on an intention-to-treat
basis. This presents particular challenges in a clinical
trial, such as this, where effective clinician and patient
blinding of treatment allocation is impossible.
Blinding of assessments
In a trial of a physical device such as this, patient and clin-
ical blinding is impossible. We therefore propose to per-
form blinded assessment of the maximum proportion of
the outcome measures. The following measures will be
blinded to group allocation:
1. All initial, baseline data, including PSG staging and
scoring.
2. Cognitive test battery.
3. Spirometry.
4. Quality of life and sleep questionnaires.The clinical scenarios outlined below will be managed
as described. Both of the first two scenarios occurred
during the feasibility trial.
Unable to continue with CPAP
Any participant who chooses to cease CPAP treatment
will remain in the study for 3 months. The test collec-
tion battery will proceed as planned.
Hospital discharge prior to end of treatment period
To continue the proposed randomized controlled trial in
the home is beyond the scope of the study, therefore the
treatment period will cease at hospital discharge. The
end study data collection battery will be performed in
the week prior to discharge and all obtained results will
be treated as ‘last observation carried forward’.
Randomized group cross-over
Patients with OSA who are randomized to usual care
but then proceed to be treated with CPAP or noninva-
sive ventilatory support will remain in their allocated
group for primary analysis purposes.
Trial data management
Each site will be responsible for local storage of hard-copy
data, which will be entered online into a centralized data-
base. Automated, digital data capture methods will be used
wherever possible. Sleep studies will be performed locally
and data transferred electronically to the coordinating
centre for analysis. This process has been successfully used
by the research team in a previous interlaboratory con-
cordance trial [30].
Estimated subject numbers
This is a three-month treatment trial at a time where
there is profound disruption in the life of the study par-
ticipants. Over this acute period, direct measurements of
quality of life and performance in rehabilitation will not
demonstrate the efficacy or otherwise of CPAP. The
feasibility study clearly demonstrated that there was sub-
stantial variability in quality of life post injury, unrelated
to OSA or CPAP, thus rendering these outcomes unsuit-
able for demonstrating short-term improvement in a
study sample of constrained size. We are, therefore, bas-
ing our sample size calculations on neurocognitive per-
formance, a number of measures of which form our test
battery. The specific neurocognitive test in the test bat-
tery, which is best characterized in both the spinal popu-
lation and OSA, is the PASAT. Lower (worse) PASAT
scores correlate with sleep fragmentation severity in the
able-bodied [31] and OSA severity in quadriplegia [15].
Lower PASAT scores are also associated with diminished
frontal lobe function, as assessed by functional magnetic
resonance imaging [32] and a mean difference in PASAT
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without cognitive impairment in multiple sclerosis [33].
In the able-bodied with OSA, those adherent to CPAP
over three months have a PASAT score 18 units higher
than those who are not (standard deviation of 33) [34].
Assuming a mean difference between the study arms of
18 [34], a standard deviation of 33, a power of 0.8, an α
value of 0.05 and a nonadherence to CPAP rate of 15%,
150 subjects will be randomized. To ensure that 150 partic-
ipants complete the study, we estimate that approximately
820 admissions with quadriplegia will be required across
our collaborating centres (at least 8 of 44 admissions will
meet the inclusion criteria, fail to meet the exclusion cri-
teria, agree to participate, have OSA and tolerate CPAP).
This sample is also adequate to detect any true difference
between secondary outcomes, such as sleepiness (KSS
number required = 44).
Adherence with therapy
All usage data collected by the treatment devices will be
downloaded weekly and analyzed fully. Based on previ-
ous research in the able-bodied population with OSA,
improvements in memory, sleepiness and daily function
may be observed if CPAP is used for 4 hours per night
for five days out of every seven [35,36]. Those subjects
who use CPAP for at least this amount will be classified
as ‘adherent’ for each week of the study
Statistical analyses
Usage data from the CPAP devices will be described and
subjects classified as adherent, as described. The propor-
tion of subjects continuing to use CPAP over the three
months of treatment will be plotted and examined using
survival (Kaplan-Meier) analysis. Statistics describing the
distribution of CPAP usage, average numbers of hours
used per night, and so on, will be calculated.
Changes in neurocognitive performance, AQoL, BNSQ
and KSS will be examined with paired t tests, repeated
measures analysis of variance and generalized linear
mixed models, as appropriate. The rate of autonomic
dysreflexia and the time course of development will be
compared with χ squared and mixed model regression
modelling as appropriate. Exploratory linear and logistic
regression modelling will be performed to determine
whether the average number of hours used or the likeli-
hood of adherence can be predicted by any of the
groups’ baseline characteristics.
Project governance and administrative support
The chief investigator (Dr Berlowitz) will be responsible
for overall project management, but is assisted and advised
by a project steering committee comprised of the collabor-
ating researchers and administrative support from the ad-
ministering coordinating institution. Additional supportand membership has been seconded from the partner or-
ganizations. The project steering committee will meet
regularly and all agendas and minutes circulated to all
stakeholders. Funding agreements will be entered into be-
tween all collaborating agencies and the administering in-
stitution. The project will be supported by a part-time
project manager.
An outcomes committee will be established as detailed
above and an independent Data Monitoring Committee
will be externally appointed by the Australasian Clinical
Trials Network.
Follow-up at trial completion
Participants in the treatment group will be given their
mask and CPAP device at the end of the 3 months to
enable them to continue treatment of their OSA. Those
randomized to the control group will be fully supported
to commence CPAP treatment and also offered a mask
and CPAP device for ongoing use. All participants will
be referred to their local respiratory or sleep clinic as ap-
propriate for ongoing management of their OSA.
Discussion
This trial will determine the effectiveness of nocturnal
CPAP in the acute quadriplegic population. In particular,
improvement in cognitive performance in this group
may improve their ability to engage with the rehabilita-
tion process and allow them to participate more fully in
life following the initial rehabilitation phase. The pro-
found reduction in physical functioning that character-
izes quadriplegia means a greater reliance on cognitive
functioning for work and participation in family and
community life post injury. Any therapy that optimizes
cognitive function is potentially of great significance to
those with quadriplegia, their families, friends and
colleagues.
Trial status
The trial commenced recruitment in July 2009. Recruit-
ment will cease when 150 trial participants have been
randomized. It is anticipated that this target will be
reached by mid-2015.
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